Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

GAM Multistock - Health Innovation Eq-USD B

Ranked 1 out of 2 in - Pharmaceuticals & Health Care over 12 months
All calculations are in EUR unless stated

Managed by

Christophe Eggmann

Christophe Eggmann is Portfolio Manager of the JB Health Innovation Fund. He joined GAM Group in November 2010. Prior to that, he held various positions as a fund manager and equity analyst at Bank Hofmann, Rothschild Bank and Credit Suisse. Christophe Eggmann holds a Master in Business Administration and Economics from the University of Neuchâtel and is a CFA Charterholder. He is based in Zurich.

Objective

The fund seeks to achieve long-term capital growth by investing globally in innovation-driven companies active in all health-care sub-sectors (pharmaceuticals, biotechnology, health-care services & supplies, medical technology, specialty pharmaceuticals and generics). The Fund is suitable for equity investors with a long-term horizon and appropriate risk awareness who wish to complement their portfolio with a concentrated investment in the health-care sector.

Showing fund performance in Lithuania View performance globally

Performance

Pharmaceuticals & Health Care over : 31/07/2016 - 31/07/2017
  • Rank 1/2 Total Return
  • Rank 2/2 Standard Deviation
  • Rank 2/2 Max Drawdown
Fund Name Currency Return
1 GAM Multistock - Health Innovation Eq-USD B EUR

5.0%

2 SEB Medical EUR

-0.9%

Total Return

Quarterly Performance

to 30/06/2017 Annual Q1 Q2 Q3 Q4
2017 12.0% -0.4%
2016 -15.4% -19.7% 6.2% -0.7% -0.1%
2015 21.5% 26.6% 1.1% -15.1% 11.8%
2014 50.6% 7.9% 8.4% 14.9% 12.1%
2013 57.3% 17.6% 8.2% 19.0% 3.9%
2012 25.0% 13.5% 10.1% 9.5% -8.7%
2011 15.2% -0.3% 2.5% -3.5% 16.8%
2010 18.3% 18.1% -7.4% 0.2% 8.0%
2009 1.1% 0.6% 0.2% 1.2% -1.0%
2008 2.0% 16.0% -11.1%

Month by Month Performance

Returns Vs Risk

Asset Allocation

Breakdown

28/02/2017

Top 10 Holdings

Stock Size
Gilead Sciences Inc ORD 5.80
Pfizer Inc ORD 5.45
Roche Holding AG Par 4.97
Hologic Inc ORD 4.22
Celgene Corp ORD 4.17
Amgen Inc ORD 3.84
Esperion Therapeutics Inc ORD 3.75
Bristol-Myers Squibb Co ORD 3.33
SAGE Therapeutics Inc ORD 3.10
Nevro Corp ORD 3.03
31/03/2017

Registered For Sale In

  1. Austria
  2. Belgium
  3. Bulgaria
  4. Denmark
  5. Estonia
  6. Finland
  7. France
  8. Germany
  9. Iceland
  10. Italy
  11. Latvia
  12. Liechtenstein
  13. Lithuania
  14. Luxembourg
  15. Netherlands
  16. Norway
  17. Singapore
  18. Spain
  19. Sweden
  20. Switzerland
  21. United Kingdom

Fund Info

  • Launch date31/01/2008
  • Share Class size100Mn
  • Base currencyUSD
  • ISIN LU0329426950

Purchase Info

  • Min. initial investment0
  • Min. regular additional investment0

Charges

  • Annual management1.60%

Related News

Pfizer power play: healthcare stars react to $14bn deal

Citywire Selector canvassed sector specialists on what the pharma giant’s latest purchase means for M&A and long-term investments.

Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in the currency and currencies indicated).